Clinical Trial Update: Safety and Pharmacokinetics of Recombinant Anti-EGFr Antibody in Patients With Metastatic Colorectal Cancer [Phase 1]

View source ↗

Summary

This Phase 1 clinical trial update reports safety and pharmacokinetics data for a recombinant anti-EGFr antibody in patients with metastatic colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Recombinant anti-EGFr antibody (Anti-EGFR antibody)

Snippet

Sponsor: Sichuan Kelun Pharmaceutical Co., Ltd | Conditions: Metastatic Colorectal Cancer | Phase 1 | Status: UNKNOWN